Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib Maintenance Post-Allo-HSCT in FLT3+ AML
NCT02400255Phase 2Completed
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Sep 2015
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crenolanib in acute myeloid leukemia (AML), sponsored by AROG Pharmaceuticals, Inc.. Started Sep 2015; status: completed.
02
Drugs
crenolanib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02400255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02400255.